Intervacc (Sweden) Insiders
| IVACC Stock | SEK 1.03 0.07 7.29% |
Intervacc employs about 13 people. The company is managed by 15 executives with a total tenure of roughly 66 years, averaging almost 4.0 years of service per executive, having 0.87 employees per reported executive. Breaking down Intervacc's management performance can provide insight into the firm performance.
| JanIngmar Flock CEO CEO, Chief Scientific Officer, Director |
| Andreas Andersson CEO Chief Executive Officer |
Intervacc |
Intervacc Management Team Effectiveness
The company has return on total asset (ROA) of (0.0991) % which means that it has lost $0.0991 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1689) %, meaning that it generated substantial loss on money invested by shareholders. Intervacc's management efficiency ratios could be used to measure how well Intervacc manages its routine affairs as well as how well it operates its assets and liabilities.Intervacc Workforce Comparison
Intervacc AB is rated second overall in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 1,697. Intervacc maintains roughly 13.0 in number of employees contributing less than 1% to stocks in Biotechnology industry.
Intervacc AB Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Intervacc AB Price Series Summation is a cross summation of Intervacc price series and its benchmark/peer.
Intervacc Notable Stakeholders
An Intervacc stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Intervacc often face trade-offs trying to please all of them. Intervacc's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Intervacc's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| JanIngmar Flock | CEO, Chief Scientific Officer, Director | Profile | |
| Andreas Andersson | Chief Executive Officer | Profile | |
| Rune Bergman | Chairman of the Board, Director Sales, Business Developer | Profile | |
| Bjorn Sjostrand | Chairman of the Board | Profile | |
| Andreas Johansson | Vice President - Supply Chain Management | Profile | |
| Jan Persson | Chief Financial Officer | Profile | |
| Newton Aguiar | Director | Profile | |
| Bert Urlings | Director | Profile | |
| Stefan Stahl | Independent Director | Profile | |
| Marianne Hansson | Director | Profile | |
| Torben Joergensen | Director | Profile | |
| Olof Zachrisson | Director Clinical Development | Profile | |
| Bengt Guss | Independent Director | Profile | |
| Patrik Hellberg | Chief Officer | Profile | |
| Andrew Waller | Chief Officer | Profile |
About Intervacc Management Performance
The success or failure of an entity such as Intervacc AB often depends on how effective the management is. Intervacc management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Intervacc management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Intervacc management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Intervacc AB , a biotechnology company, engages in the research and development of veterinary vaccines using recombinant proteins for animal health. The company has a collaboration with the Karolinska Institute. Intervacc operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 12 people.
Please note, the imprecision that can be found in Intervacc's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Intervacc AB. Check Intervacc's Beneish M Score to see the likelihood of Intervacc's management manipulating its earnings.
Intervacc Workforce Analysis
Traditionally, organizations such as Intervacc use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Intervacc within its industry.Intervacc Manpower Efficiency
Return on Intervacc Manpower
| Revenue Per Employee | 403.2K | |
| Revenue Per Executive | 349.4K | |
| Net Loss Per Employee | 2.3M | |
| Net Loss Per Executive | 2M |
Additional Tools for Intervacc Stock Analysis
When running Intervacc's price analysis, check to measure Intervacc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intervacc is operating at the current time. Most of Intervacc's value examination focuses on studying past and present price action to predict the probability of Intervacc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intervacc's price. Additionally, you may evaluate how the addition of Intervacc to your portfolios can decrease your overall portfolio volatility.